The short answer
Estradiol vaginal cream 0.01%, sold as Estrace cream and generics, is approved for moderate-to-severe symptoms of vulvar and vaginal atrophy due to menopause. The label advises using the lowest dose and regimen that controls symptoms, with periodic reassessment. Unlike Estring, its current label still carries the older boxed warning.
Boxed warning on the current Estrace cream label
The current Estrace vaginal cream label (DailyMed, May 2024) carries a boxed warning for endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia, even though blood levels with low-dose vaginal use are much lower than with systemic estrogen. In November 2025 the FDA asked hormone therapy manufacturers to remove some boxed-warning language, but a product's warning changes only when its own label is revised.
Contraindications on the label include undiagnosed abnormal genital bleeding, current or past breast cancer, estrogen-dependent cancer, current or past blood clots, current or past stroke or heart attack, liver disease, known blood-clotting disorders, serious allergic reaction to the product, and pregnancy.
Current label check
The medication-specific claims on this page were checked against these current product labels on 2026-10-03.
| Product label | Label date | Boxed warning on that label |
|---|---|---|
| Estrace (estradiol) vaginal cream 0.01% | 2024-05-29 | Endometrial cancer, cardiovascular disorders, breast cancer, probable dementia |
Established evidence
FDA-approved use
Treatment of moderate-to-severe symptoms of vulvar and vaginal atrophy due to menopause.
How it is used
The cream is measured with a marked applicator and inserted into the vagina, typically daily for a short start-up period and then less often for maintenance, as directed by the prescriber. Some people are also directed to apply a small amount to the vulva. The label says to use the lowest dose and regimen that controls symptoms and to reassess periodically whether treatment is still needed.
Cream vs inserts vs ring
| Form | Products | Dose flexibility | Mess |
|---|---|---|---|
| Cream | Estrace cream, Premarin cream | High | Some |
| Insert | Vagifem, Yuvafem, Imvexxy | Fixed | Minimal |
| Ring | Estring | Fixed, 90 days | None |
Established evidence
Common side effects
- Vaginal irritation or discharge
- Breast tenderness
- Spotting, which should be reported
Practical notes
Oil-based creams can weaken latex condoms; check the product label and ask a pharmacist if this matters to you. Partners may be exposed to small amounts if cream is used right before sex.
Questions to ask a healthcare professional
- How often should I use it after the start-up phase?
- Would an insert or ring be easier?
- Is it safe with my cancer history?
Questions, answered
What people ask about Estrace cream
Is Estrace cream the same as Premarin cream?+
No. Estrace cream contains estradiol; Premarin cream contains conjugated estrogens.
Does Kindr Health offer estradiol cream?+
This page is educational and does not state or imply availability through Kindr Health.
Kindr Health does not claim to offer Estrace cream on this page. Availability and prescribing are not implied.
A broader care pathway
Explore menopause care
Learn how Kindr Health care pathways work. An educational page is not a statement that this medication is available or appropriate for you.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- Estrace (estradiol vaginal cream, USP 0.01%) prescribing information (2024) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfc41fcd-c5ba-4b25-b647-cf04d3988b3e
- FDA initiates removal of boxed warnings from menopausal hormone therapy products (2025) — U.S. Department of Health and Human Services / FDA. www.hhs.gov/press-room/fact-sheet-fda-initiates-removal-of-black-box-warnings-from-menopausal-hormone-replacement-therapy-products.html
- FDA approves labeling changes to menopausal hormone therapy products (first six labels) (2026) — U.S. Food and Drug Administration. www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
- The 2020 genitourinary syndrome of menopause position statement (2020) — The Menopause Society (Menopause journal). pubmed.ncbi.nlm.nih.gov/32852449
This resource is educational and does not replace individualized medical advice. Do not start, stop, or change a prescription without guidance from a licensed healthcare professional.